Digital Transformation

MMTEC dodged delisting, but a one-year Nasdaq monitor and a history of reverse splits raise questions about its long-term viability on US exchanges.

A bedding donation is more than charity; it's a strategic move. See how Bedsure leverages purpose to compete in the demanding home textiles market.

CardCash's record November reveals a major shift in consumer behavior, where shoppers are using discounted gift cards as a tool to fight inflation.

Adagio Medical lands ex-Medtronic exec Sean Salmon. His mission: drive its novel cryoablation tech to disrupt the competitive cardiac arrhythmia market.

Xtant Medical's new nanOss Strata bone graft isn't just an update; it's a strategic move to disrupt the orthobiologics market. Here's why it matters.

New Phase 2 data shows Elicio's off-the-shelf therapy ELI-002 7P induces "antigen spreading," creating a personalized anti-tumor response.

Cadrenal Therapeutics acquires a novel Phase 2 drug for a deadly clotting disorder, a strategic move targeting an underserved $1 billion market.

The return of a critical antibiotic after 14 years via a new, ultra-fast FDA pathway signals a major shift in U.S. industrial and health policy.

Biomerica's regulatory win in Egypt is more than a market entry; it's a strategic move to disrupt healthcare with low-cost, rapid diagnostic tools.

byNordic Acquisition Corp. buys another month in its search for a Nordic tech merger, but each extension drains funds and tests investor patience.

Beyond the ad break: How TripleLift's focus on creative formats, global retail media partnerships, and AI is disrupting the programmatic advertising landscape.

Praxis Precision Medicines secures a clear path to market for its rare epilepsy drug, blending genetic science with a savvy regulatory strategy.

With a new $6.5M investment, Double is tackling the accounting talent crisis with AI that empowers professionals, not replaces them. Here's why.

As national banks celebrate rising satisfaction from digital innovation, a new study reveals a silent crisis: older customers are being left behind.

With a 2026 decision date set, Lifezone Metals is de-risking a world-class nickel project in Tanzania, promising to shake up the global battery supply chain.

The EU's landmark decision to ease rules on New Genomic Techniques opens a multi-billion dollar market, and ag-tech pioneer Cibus is ready to cash in.

Apollo Silver plans to revive a massive California silver deposit, aligning with US strategic goals. Can it overcome technical and environmental hurdles?

Bristol Myers Squibb's Opdivo gets FDA priority review, backed by landmark data suggesting it could unseat a key competitor as the new gold standard.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

As EVgo nears breakeven, it brings in a seasoned financial architect from the energy sector to steer its capital-intensive buildout toward profitability.